Skip to main content

Table 2 Safety

From: Response to anti-PD1 therapy with nivolumab in metastatic sarcomas

  Grade 1–2 Grade 3–4
On Pz (No.) NO Pz (No.) Total (No.) On Pz (No.) NO Pz (No.) Total (No.)
Hematologic
 Anemia 3 1 4
 Neutropenia 1 1
 Thrombocytopenia 1 1 2
Non-hematologic
 Diarrhea 3   3 1   1
 Pneumonitis 1   1 1   1
 Rash 3 1 4
 Hypothyroidism 6 2 8
 LFTs 8 2 10 3   3
  1. Toxicity was graded as per NCI CTCAE v4.0
  2. Pz pazopanib, 400–800 mg po daily; LFTs liver function tests abnormalities